newsfilter
← Latest News
GlobeNewswire·

Anteris Technologies Global Corp. Announces Closing of $230 Million Public Offering of Common Stock

AVR
  • Anteris Technologies Global Corp. closed an underwritten public offering of 40,000,000 common stock shares at $5.75 per share, including the full exercise of the underwriters' option.
  • The company simultaneously closed a private placement of 15,652,173 common stock shares to Medtronic plc (via a wholly owned subsidiary) at $5.75 per share.
  • Gross proceeds from both transactions totaled approximately $320 million before deducting underwriting discounts, placement agent fees, & estimated expenses.
  • Barclays, Wells Fargo Securities, & Cantor served as joint book-running managers for the public offering, while Wells Fargo acted as sole placement agent for the private placement.
  • Anteris intends to use net proceeds to advance the PARADIGM global pivotal trial for the DurAVR® Transcatheter Heart Valve, expand manufacturing capabilities, fund research for v2vmedtech, inc., & support working capital.
  • The public offering was executed under a Form S-3 shelf registration statement declared effective by the SEC on January 8, 2026.
  • Shares sold in the private placement were not registered under the Securities Act & may not be offered or sold in the U.S. except pursuant to an effective registration statement or applicable exemption.
  • The DurAVR® THV is a balloon-expandable, biomimetic valve utilizing FDA-cleared ADAPT® tissue, with patient enrollment in the PARADIGM trial beginning in Denmark during Q4 2025.